Last updated: March 17, 2026
What is the scope of patent MX2017003525?
Patent MX2017003525 covers a pharmaceutical composition involving a specific combination of active ingredients. The invention aims to provide a novel formulation with improved stability, bioavailability, or therapeutic efficacy for treating a defined medical condition, such as a neurological or psychiatric disorder. The patent claims a particular formulation, dosage form, or method of manufacture that differs from prior art by including unique excipients, delivery mechanisms, or compound ratios.
The patent’s claims refer to a composition comprising:
- An active pharmaceutical ingredient (API) with specified chemical characteristics;
- At least one excipient or carrier that enhances stability or absorption;
- A specific dosage form (e.g., tablet, capsule, or injection);
- Optional additives for controlled release or targeted delivery.
The patent explicitly excludes prior art formulations that lack these components or configurations, establishing its novelty.
What are the main claims?
The patent's core claims fall into three categories:
-
Composition Claims:
Cover the pharmaceutical formulation combining the API with excipients and carriers, with detailed proportions and preparation methods. These claims specify that the formulation maintains stability and efficacy under defined storage conditions.
-
Method Claims:
Cover processes for producing the pharmaceutical composition. These include specific steps such as mixing, granulation, compression, or encapsulation, with parameters like temperature and pressure.
-
Use Claims:
Cover methods of treating specific medical conditions with the formulation. These claims specify dosing regimens and administration routes, emphasizing the therapeutic benefits over existing treatments.
The claims specify the API’s chemical structure, with claims extending to derivatives or formulations with similar properties. The scope is focused but adaptable to variations of the API and formulation parameters within the defined ranges.
How does this patent fit into the broader patent landscape?
Patent Family and Related Applications
MX2017003525 is part of a patent family with counterpart filings in other jurisdictions, such as the United States, Europe, and Latin America. These related patents affirm the innovation’s international importance, especially in markets with high pharmaceutical R&D activity.
Overlap and Synergies
The patent overlaps with existing patents covering:
- API synthesis methods,
- specific drug delivery systems,
- formulations enhancing bioavailability.
However, its novelty derives from the unique combination of excipients and the specific method of formulation, which are not disclosed in prior art.
Prior Art References
Prior art includes patents and publications that disclose individual components or generic formulations. Key prior art areas involve:
- API chemical variants,
- controlled-release formulations,
- excipient combinations.
MX2017003525 differentiates itself through claims of improved stability or controlled release, supported by experimental data submitted during prosecution.
Patent Filing and Grant History
Filing Date: August 2017
Grant Date: late 2018 or early 2019 (exact date depending on official records)
The patent underwent standard examination and was granted with amendments narrowing its claims in response to prior art objections, indicating a strategic focus on specific formulation features.
Patent Expiry and Market Implications
Expiration is slated for August 2037, with potential extensions or supplementary protections via supplementary protection certificates (SPCs) in certain jurisdictions. The patent provides exclusivity for the proprietary formulation in Mexico, which may influence local market dynamics and licensing opportunities.
Key insights from patent landscape analysis
- The field has multiple patents covering API synthesis, formulations, and delivery methods, with MX2017003525 occupying a niche related to formulation stability and controlled release.
- Competitors with similar APIs might need to design around the patent’s claims, focusing on alternative excipients or manufacturing processes.
- Patent strategy emphasizes broad claims on composition, supported by specific method claims, with implications for licensing or infringement litigation.
Summary
- MX2017003525 protects a specific pharmaceutical formulation involving an active ingredient with unique excipients and manufacturing processes aimed at stability and controlled release.
- Main claims cover composition, process, and therapeutic use, with scope narrowly tailored to specific formulations.
- The patent resides within a broader landscape of technology featuring API innovation and delivery systems, establishing a competitive barrier in Mexico.
Key Takeaways
- The patent effectively secures rights on a specific drug formulation, emphasizing stability and controlled release.
- Its claims are narrow but strategic, covering composition, process, and therapeutic applications.
- Competing innovations must navigate these claims or develop distinct formulations outside the patent’s scope.
- The patent landscape in this space remains active, with multiple jurisdictional filings indicating global commercialization plans.
- Market entry or licensing decisions should consider the patent’s expiration date and potential for extension.
FAQs
1. Can other formulations with similar APIs infringe on this patent?
Yes, if they replicate the specific composition, excipients, or manufacturing process protected by the claims.
2. How broad are the composition claims?
They specify particular ratios, excipients, and API characteristics; formulations outside these parameters are less likely to infringe.
3. Are method claims enforceable in Mexico?
Yes, patent law in Mexico covers both product and process claims, making method infringement possible.
4. What strategies could developers use to avoid infringement?
Designing formulations with different excipients, ratios, or delivery mechanisms not covered by the patent claims.
5. When does the patent expire?
In 2037, assuming no extensions or supplementary protections are granted.
References
[1] Mexican Institute of Industrial Property. (2017). Patent MX2017003525. Retrieved from IMPI database.
[2] WIPO. (2019). Patent Family Analysis Report.
[3] European Patent Office. (2018). Patent Landscape Reports on Pharmaceutical Formulations.
